Dyax Corp.
300 Technology Square
Cambridge,
MA 02139
United States - Map
Phone: 617-225-2500
Fax: 617-225-2501
Web Site: http://www.dyax.com
| Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications. The company uses phage display, a drug discovery technology to identify antibody, small protein, and peptide compounds for clinical development. It offers DX-88, an ecallantide, which is in late stage clinical trial development in two indications. The advanced indication for DX-88 involves the treatment of hereditary angioedema, a life-threatening inflammatory condition, which completed three Phase II trials and two Phase III trials; and the second indication for DX-88 is for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which completed a Phase I/II trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. The company also has other biopharmaceutical discovery and development programs, primarily DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. It also provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. The company has co-development collaboration agreements with Athera, CSIRO, and Syntonix Pharmaceuticals; and licensing agreements with Cubist Pharmaceuticals, sanofi-aventis, and Fovea Pharmaceuticals. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Henry E. Blair , 66
Co-Founder and Chairman |
$
947.00K |
$
35.00K | Mr. Gustav A. Christensen ,
Chief Exec. Officer, Pres |
$
573.00K | N/A | Mr. George Migausky , 55
Chief Financial Officer, Principal Accounting Officer and Exec. VP |
$
222.00K | N/A | Dr. Ivana Magovcevic-Liebisch Ph.D., J.D., 42
Exec. VP of Corp. Devel. and Gen. Counsel |
N/A
| N/A | Mr. Stephen S. Galliker CPA, 63
Consultant |
$
272.00K |
$
606.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.11% Nasdaq 0.00%
Profile
